Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Ilaris, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Simponi, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, sebetralstat, and others. Its therapeutic areas include hematology, ophthalmology, influenza, endocrinology, dermatology, oncology, neurology, immunology, lysosomal storage disorder, hereditary angioedema, and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; and others.


TSX:DHT.UN - Post by User

User Avatar Image
(64)
•••
  • SONOFFERGUSX
Comment by SONOFFERGUSon May 14, 2025 5:50pm
52 Views
Post# 36574082

RE:RE:RBC Raises Target

RE:RE:RBC Raises TargetGreat news for DHT overshadowed by bad news for big pharma, down 7+% since last week thanks to Trump's executive order.

I am waiting for the earnings transcript, but it sure sounded to me that DHT sees the units as extremely undervalued and is looking to reward its institutional investors for sticking with them.

As you say, if they fire up the NCIB on Tuesday then SP is going to move up fast.  They were buying in the $14s last summer, and NAV has gone up a lot since then.  They are waiting to book deals until the ground stops moving, so what else are they going to do?  Q2 is half-way done and they have nothing to talk about.  The buyback will be the headline.

CEO has been taking his comp in cash and the mgmt bonus formula has been set at a nice low unit price, which means to me that they're going to buy buy buy.

It is of course difficult to separate the state of pharma as a whole from DHT's position in the space.  It is hard to see how Trump looking to get cheaper Ozempic for Medicare/Medicaid as hitting DHT's portfolio unless things get really crazy.  It's also hard to see how Chairman Trump's executive order survives the courts.  IMHO, the vibes for pharma are going to turn soon and that will put more wind in DHT's sails.

Anyway, whatever, WTFK.  GLTA long-suffering longs.






<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities